Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate

Journal of Neuroimmunology

Volumn 148, Issue 1-2, 2004, Pages 63-73

  Jung, Stefan ^a,b   Siglienti, Ines ^a,c   Grauer, Oliver ^a,d   Magnus, Tim ^b   Scarlato, Guglielmo ^c   Toyka, Klaus ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Antigen presenting cell; Copaxone; Cytokine; Immunomodulation; Multiple sclerosis

Indexed keywords

GLATIRAMER; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MYELIN BASIC PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DENSITY; DOSE RESPONSE; IMMUNOMODULATION; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM;

EID: 1242272715     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2003.11.014     Document Type: Article

References (49)

1. Abe T., Swieter M., Imai T., Hollander N.D., Befus A.D. Mast cell heterogeneity: two-dimensional gel electrophoretic analyses of rat peritoneal and intestinal mucosal mast cells. Eur. J. Immunol. 20:1990;1941-1947.
2. Aharoni R., Teitelbaum D., Arnon R. T suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis. Eur. J. Immunol. 23:1993;17-25.
3. Aharoni R., Teitelbaum D., Sela M., Arnon R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 94:1997;10821-10826.
4. Aharoni R., Teitelbaum D., Arnon R., Sela M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc. Natl. Acad. Sci. U. S. A. 96:1999;634-639.
5. Arnon R. The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. Immunol. Lett. 50:1996;1-15.
6. Baron P., Constantin G., Meda L., Scarpini E., Scarlato G., Trinchieri G., Monastra G., Rossi F., Cassatella M.A. Cultured human monocytes release proinflammatory cytokines in response to myelin basic protein. Neurosci. Lett. 252:1998;151-154.
7. Ben-Nun A., Mendel I., Bakimer R., Fridkis H.M., Teitelbaum D., Arnon R., Sela M., Kerlero-de Rosbo N. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. J. Neurol. 243:1996;S14-S22.
8. Bornstein M.B., Miller A., Slagle S., Weitzman M., Crystal H., Drexler E., Keilson M., Merriam A., Wassertheil S.S., Spada V.et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N. Engl. J. Med. 317:1987;408-414.
9. Bright J.J., Xin Z., Sriram S. Superantigens augment antigen-specific Th1 responses by inducing IL-12 production in macrophages. J. Leukoc. Biol. 65:1999;665-670.
10. Constantinescu C.S., Goodman D.B., Hilliard B., Wysocka M., Cohen J.A. Murine macrophages stimulated with central and peripheral nervous system myelin or purified myelin proteins release inflammatory products. Neurosci. Lett. 287:2000;171-174.
11. Cope A.P., Liblau R.S., Yang X.D., Congia M., Laudanna C., Schreiber R.D., Probert L., Kollias G., McDevitt H.O. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J. Exp. Med. 185:1997;1573-1584.
12. Crisi G.M., Santambrogio L., Hochwald G.M., Smith S.R., Carlino J.A., Thorbecke G.J. Staphylococcal enterotoxin B and tumor-necrosis factor-alpha-induced relapses of experimental allergic encephalomyelitis: protection by transforming growth factor-beta and interleukin-10. Eur. J. Immunol. 25:1995;3035-3040.
13. de Seze J., Edan G., Labalette M., Dessaint J.P., Vermersch P. Effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a phase 1 trial. Ann. Neurol. 47:2000;686.
14. de Waal-Malefyt R., Abrams J., Bennett B., Figdor C.G., de Vries J.E. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174:1991;1209-1220.
15. Duda P.W., Schmied M.C., Cook S.L., Krieger J.I., Hafler D.A. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 105:2000;967-976.
16. Eylar E.H., Kniskern P.J., Jackson J.J. Myelin basic proteins. Methods Enzymol. 32:1971;323-341.
17. Frei K., Eugster H.-P., Bopst M., Constantinescu C.S., Lavi E., Fontana A. Tumor necrosis factor α and lymphotoxin α are not required for induction of acute experimental autoimmune encephalomyelitis. J. Exp. Med. 185:1997;2177-2182.
18. Fridkis-Hareli M., Strominger J.L. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J. Immunol. 160:1998;4386-4397.
19. Fridkis-Hareli M., Teitelbaum D., Gurevich E., Pecht I., Brautbar C., Kwon O.J., Brenner T., Arnon R., Sela M. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - specificity and promiscuity. Proc. Natl. Acad. Sci. U. S. A. 91:1994;4872-4876.
20. Fridkis-Hareli M., Teitelbaum D., Arnon R., Sela M. Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells. Cell. Immunol. 163:1995;229-236.
21. Fridkis-Hareli M., Teitelbaum D., Pecht I., Arnon R., Sela M. Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells. Int. Immunol. 9:1997;925-934.
22. Gran B., Tranquill L.R., Chen M., Bielekova B., Zhou W., Dhib-Jalbut S., Martin R. Mechanisms of immunomodulation by glatiramer acetate. Neurology. 55:2000;1704-1714.
23. Grauer O., Wohlleben G., Seubert S., Weishaupt A., Kämpgen E., Gold R. Analysis of maturation stages of rat bone marrow-derived dendritic cells using an improved culture technique. Histochem. Cell Biol. 117:2002;351-362.
24. Hussien Y., Sanna A., Soderstrom M., Link H., Huang Y.M. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J. Neuroimmunol. 121:2001;102-110.
25. Jacob C.O., McDevitt H.O. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature. 331:1988;356-358.
26. Jacob C.O., Aiso S., Michie S.A., McDevitt H.O., Acha-Orbea H. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc. Natl. Acad. Sci. U. S. A. 87:1990;968-972.
27. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., Myers L.W., Panitch H.S., Rose J.W., Schiffer R.B., Vollmer T., Weiner L.P., Wolinsky J.S. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 45:1995;1268-1276.
28. Jung S., Zielasek J., Köllner G., Donhauser T., Toyka K., Hartung H.-P. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 68:1996;1-11.
29. Koerner H., Lemckert F.A., Chaudhri G., Etteldorf S., Sedgwick J.D. Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system. Eur. J. Immunol. 27:1997;1973-1981.
30. Ledeen R.W., Chakraborty G. Cytokines, signal transduction, and inflammatory demyelination: review and hypothesis. Neurochem. Res. 23:1998;277-289.
31. Matsuyama S., Koide Y., Yoshida T.O. HLA class II molecule-mediated signal transduction mechanism responsible for the expression of interleukin-1 beta and tumor necrosis factor-alpha genes induced by a staphylococcal superantigen. Eur. J. Immunol. 23:1993;3194-3202.
32. Neuhaus O., Farina C., Yassouridis A., Wiendl H., Then B.F., Dose T., Wekerle H., Hohlfeld R. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc. Natl. Acad. Sci. U. S. A. 97:2000;7452-7457.
33. Reichert F., Rotshenker S. Galectin-3/MAC-2 in experimental allergic encephalomyelitis. Exp. Neurol. 160:1999;508-514.
34. Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., Luer W., Poser S. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology. 44:1994;1523-1526.
35. Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., Luer W., Helwig A., Poser S. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann. Neurol. 37:1995;82-88.
36. Rott O., Fleischer B., Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur. J. Immunol. 24:1994;1434-1440.
37. Schlegel P.G., Aharoni R., Chen Y., Chen J., Teitelbaum D., Arnon R., Sela M., Chao N.J. A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. Proc. Natl. Acad. Sci. U. S. A. 93:1996;5061-5066.
38. Smeltz R.B., Swanborg R.H. Concordance and contradiction concerning cytokines and chemokines in experimental demyelinating disease. J. Neurosci. Res. 51:1998;147-153.
39. Teitelbaum D., Meshorer A., Hirshfeld T., Arnon R., Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1:1971;242-248.
40. Teitelbaum D., Webb C., Meshorer A., Arnon R., Sela M. Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur. J. Immunol. 3:1973;273-293.
41. Teitelbaum D., Webb C., Bree M., Meshorer A., Arnon R., Sela M. Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. Clin. Immunol. Immunopathol. 3:1974;256-262.
42. Teitelbaum D., Fridkis Hareli M., Arnon R., Sela M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 64:1996;209-217.
43. Teitelbaum D., Arnon R., Sela M. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. Proc. Natl. Acad. Sci. U. S. A. 96:1999;3842-3847.
44. Varadhachary A.S., Perdow S.N., Hu C., Ramanarayanan M., Salgame P. Differential ability of T cell subsets to undergo activation-induced cell death. Proc. Natl. Acad. Sci. U. S. A. 94:1997;5778-5783.
45. Vieira P.L., Heystek H.C., Wormmeester J., Wierenga E.A., Kapsenberg M.L. Glatiramer acetate (copolymer-1, Copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J. Immunol. 170:2003;4483-4488.
46. Wekerle H., Lassmann H. Immunology of multiple sclerosis. Compston A., Ebers G.C., Lassmann H., McDonald I., Matthews B., Wekerle H. McAlpine's Multiple Sclerosis. 1998;379-408 Churchill Livingstone, London.
47. Wolinsky J. Glatiramer acetate. Hawkins C.P., Wolinsky J. Principles of Treatments in Multiple Sclerosis. 2000;71-94 Butterworth-Heinemann, Oxford.
48. Zhang X., Brunner T., Carter L., Dutton R.W., Rogers P., Bradley L., Sato T., Reed J.C., Green D., Swain S.L. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J. Exp. Med. 185:1997;1837-1849.
49. Zhang M., Chan C.C., Vistica B., Hung V., Wiggert B., Gery I. Copolymer 1 inhibits experimental autoimmune uveoretinitis. J. Neuroimmunol. 103:2000;189-194.